Original Article
  

Evaluating the Efficacy of Intranasal Montelukast in Pediatric Acute Asthma Attacks: A Single-Blinded, Placebo-controlled Clinical Trial

Abstract

Asthma is a common chronic respiratory disease in children, often leading to acute exacerbations marked by dyspnea, cough, and wheezing, which frequently necessitate emergency medical care. While standard therapies are effective, the exploration of novel drug delivery routes continues. Oral montelukast is a recognized treatment, but the efficacy of its intranasal formulation for acute attacks remains underexplored. This study aimed to evaluate the clinical effectiveness of intranasal montelukast as an adjunct therapy for pediatric asthma exacerbations.
A single-blinded, placebo-controlled, single-center trial was conducted involving children aged 2-12 years hospitalized with moderate to severe acute asthma. Participants were randomized to receive either intranasal montelukast or a placebo alongside standard care. Key outcomes, including the Pulmonary Index Score (PIS), respiratory rate, oxygen saturation, and length of hospital stay, were systematically assessed.
The analysis of 25 patients in each group revealed no significant baseline differences. The intranasal montelukast group demonstrated a statistically significant and sustained reduction in PIS scores at critical intervals (8, 12, and 24 hours) compared to the placebo group. Improvements in respiratory rate and oxygen saturation were also more pronounced with the active treatment. Notably, the mean hospital stay was significantly shorter for the montelukast group (2.16 days) than the placebo group (3.12 days).
In conclusion, intranasal montelukast shows significant promise as an effective adjunct therapy for acute pediatric asthma, correlating with accelerated clinical improvement and a reduced duration of hospitalization. These encouraging results justify further investigation through larger, multicenter trials to definitively establish its efficacy and safety profile.

1. Pardue Jones B, Fleming GM, Otillio JK, Asokan I, Arnold DH. Pediatric acute asthma exacerbations: Evaluation and management from emergency department to intensive care unit. J Asthma Off J Assoc Care Asthma. 2016;53(6):607–17.
2. Mthembu N, Ikwegbue P, Brombacher F, Hadebe S. Respiratory Viral and Bacterial Factors That Influence Early Childhood Asthma. Front Allergy. 2021;2:692841.
3. Ferrante G, La Grutta S. The Burden of Pediatric Asthma. Front Pediatr. 2018;6:186.
4. Mallol J, Aguirre V, Mallol-Simmonds M, Matamala-Bezmalinovic A, Calderón-Rodriguez L, Osses-Vergara F. Changes in the prevalence of asthma and related risk factors in adolescents: Three surveys between 1994 and 2015. Allergol Immunopathol (Madr). 2019;47(4):313–21.
5. Taylor YJ, Tapp H, Shade LE, Liu TL, Mowrer JL, Dulin MF. Impact of shared decision making on asthma quality of life and asthma control among children. J Asthma Off J Assoc Care Asthma. 2018;55(6):675–83.
6. Ntontsi P, Photiades A, Zervas E, Xanthou G, Samitas K. Genetics and Epigenetics in Asthma. Int J Mol Sci. 2021;22(5):2412.
7. Wang Q, Ying Q, Zhu W, Chen J. Vitamin D and asthma occurrence in children: A systematic review and meta-analysis. J Pediatr Nurs. 2022;62:e60–8.
8. Li R, Guo Q, Zhao J, Kang W, Lu R, Long Z, et al. Assessing causal relationships between gut microbiota and asthma: evidence from two sample Mendelian randomization analysis. Front Immunol. 2023;14:1148684.
9. Theodosiou AA, Dorey RB, Laver JR, Cleary DW, Read RC, Jones CE. Manipulating the infant respiratory microbiomes to improve clinical outcomes: A review of the literature. J Infect. 2021;82(6):247–52.
10. Khreis H, Kelly C, Tate J, Parslow R, Lucas K, Nieuwenhuijsen M. Exposure to traffic-related air pollution and risk of development of childhood asthma: A systematic review and meta-analysis. Environ Int. 2017;100:1–31.
11. Indinnimeo L, Chiappini E, Miraglia del Giudice M. Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics. Ital J Pediatr. 2018;44:46.
12. Jones H, Lawton A, Gupta A. Asthma Attacks in Children—Challenges and Opportunities. Indian J Pediatr. 2022;89(4):373–7.
13. Xiang Y, Ji H, Zhou Y, Li F, Du J, Rasmy L, et al. Asthma Exacerbation Prediction and Risk Factor Analysis Based on a Time-Sensitive, Attentive Neural Network: Retrospective Cohort Study. J Med Internet Res. 2020;22(7):e16981.
14. Wark P a. B, Gibson PG. Asthma exacerbations . 3: Pathogenesis. Thorax. 2006;61(10):909–15.
15. Evaluation and Management of Asthma and Chronic Obstructive Pulmonary Disease Exacerbation in the Emergency Department. Emerg Med Clin North Am. 2022;40(3):539–63.
16. Scow DT, Luttermoser GK, Dickerson KS. Leukotriene Inhibitors in the Treatment of Allergy and Asthma. Am Fam Physician. 2007;75(1):65–70.
17. Montelukast, cysteinyl leukotriene receptor 1 antagonist, inhibits cardiac fibrosis by activating APJ. Eur J Pharmacol. 2022;923:174892.
18. Jullaphant T, Nakpeng T, Srichana T. Montelukast nasal spray: formulation development and in vitro evaluation. Pharm Dev Technol. 2019;24(4):494–503.
19. Wang HW, Lee JC, Wu PC, Chu YH, Lin YY, Cheng LH. Effects of montelukast on human nasal mucosa. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. 2019;276(3):761–5.
20. Jafari M, Sobhani M, Eftekhari K, Malekiantaghi A, Gharagozlou M, Shafiei A. The Effect of Oral Montelukast in Controlling Asthma Attacks in Children: A Randomized Double-blind Placebo Control Study. Iran J Allergy Asthma Immunol. 2023;22(5):413–9.
21. Zubairi ABS, Salahuddin N, Khawaja A, Awan S, Shah AA, Haque AS, et al. A randomized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation. BMC Pulm Med. 2013;13:20.
22. Demet Akbaş E, Razi CH, Andıran N. Effects of using montelukast during acute wheezing attack in hospitalized preschool children on the discharge rate and the clinical asthma score. Pediatr Pulmonol. 2021;56(7):1931–7.
23. Chaudhury A, Gaude GS, Hattiholi J. Effects of oral montelukast on airway function in acute asthma: A randomized trial. Lung India Off Organ Indian Chest Soc. 2017;34(4):349–54.
24. Ramsay CF, Pearson D, Mildenhall S, Wilson AM. Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial. Thorax. 2011;66(1):7–11.
25. Harmanci K, Bakirtas A, Turktas I, Degim T. Oral montelukast treatment of preschool-aged children with acute asthma. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2006;96(5):731–5.
26. Diamant Z, Mantzouranis E, Bjermer L. Montelukast in the treatment of asthma and beyond. Expert Rev Clin Immunol. 2009;5(6):639–58.
27. Singulair (Montelukast Sodium).
Files
IssueArticles in Press QRcode
SectionOriginal Article(s)
Keywords
Asthma attack Montelukast Pediatric asthma Pulmonary index scores
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Sadinejad M, Amini N, Tavakoli E, Sabzghabaee AM. Evaluating the Efficacy of Intranasal Montelukast in Pediatric Acute Asthma Attacks: A Single-Blinded, Placebo-controlled Clinical Trial. Iran J Allergy Asthma Immunol. 2025;:1-9.